


PHARMACEUTICAL 2023

Annovis Bio Inc. Rank 201 of 446







PHARMACEUTICAL 2023

Annovis Bio Inc. Rank 201 of 446



The relative strengths and weaknesses of Annovis Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Annovis Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Annovis Bio Inc. is the variable Net Income, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 107%, being 64% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	36,022
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,699
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	183
Other Revenues	0
Property and Equipment	0
Research and Development	16,516
Selling, General and Administrative Expense	8,996

Output Variable	Value in 1000 USD
Assets	36,022
Liabilities	7,699
Expenses	25,511
Revenues	0
Stockholders Equity	28,324
Net Income	-25,329
Comprehensive Net Income	-25,329
Economic Capital Ratio	107%

